ENDPOINTS NEWS9h
Eli Lil­ly re­veals £279M in­vest­ment in the UK through new gov­ern­ment deal
Eli Lilly plans to invest £279 million ($364 million) in the UK as part of a new government partnership in which the ...
ENDPOINTS NEWS9h
Bausch + Lom­b's stock ris­es fol­low­ing re­port of po­ten­tial bid from pri­vate eq­ui­ty firms TPG and Black­stone
Private equity firms TPG and Blackstone are working on a potential deal to buy Brent Saunders-led eye care company Bausch + ...
ENDPOINTS NEWS9h
No­var­tis used a PRV to speed Kisqal­i's lat­est in­di­ca­tion, FDA says
Novartis used one of its priority review vouchers (PRV) to speed the September approval of Kisqali in early breast cancer, ...
ENDPOINTS NEWS13h
How End­points cov­ers AI, and a chance to hear from two No­bel win­ners
More than a year ago, Endpoints News made the decision that we needed a dedicated reporter covering the use of artificial ...
ENDPOINTS NEWS8h
No­vo Nordisk files 18 law­suits against GLP-1 com­pounders in 44 days
Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo ...
ENDPOINTS NEWS13h
No­var­tis ends mid-stage IPF tri­al, will keep test­ing drug in PAH
Novartis has terminated a mid-stage trial of an oral treatment candidate for idiopathic pulmonary fibrosis, the company ...
ENDPOINTS NEWS11h
Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points
GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...
ENDPOINTS NEWS11h
Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py
The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant ...
ENDPOINTS NEWS17h
Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies
The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life ...
ENDPOINTS NEWS16h
Trans­gene shares dip as ther­a­peu­tic can­cer vac­cine dis­ap­points in Phase 2 tri­al
Transgene’s therapeutic cancer vaccine candidate has failed a mid-stage test in certain HPV-driven cancers, sending its ...
ENDPOINTS NEWS14h
Mark Pruzan­s­ki gets an­oth­er shot at MASH, join­ing as chair of In­ven­ti­va as it gets ‘much need­ed fund­ing’
After flashing warning signs in July with only enough money for that month, Inventiva has now secured a lifeline to keep its ...
ENDPOINTS NEWS16h
Catal­ent sells New Jer­sey plant to Bel­gian CD­MO, plans mov­ing HQ else­where
Novo Holdings is set to buy one less facility from Catalent as the manufacturer has sold a facility in New Jersey to a ...